Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved Ajovy for the prevention of episodic migraine in patients aged 6-17 years.
Ajovy was first approved in 2018 for the preventive treatment of migraine in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.